Cargando…

Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia

BACKGROUND: Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in North America. Previous studies have shown improved progression free survival (PFS) and response rates in unfit patients treated with obinutuzumab compared to other regimens. The aim of this study was to evaluate t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bourrier, Nicole, Landego, Ivan, Bucher, Oliver, Squires, Mandy, Streu, Erin, Hibbert, Irena, Whiteside, Theresa, Gibson, Spencer B., Geirnaert, Marc, Johnston, James B., Dawe, David E., Banerji, Versha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818183/ https://www.ncbi.nlm.nih.gov/pubmed/35123433 http://dx.doi.org/10.1186/s12885-022-09256-2

Ejemplares similares

Clinical Outcomes in a Large Canadian Centralized CLL Clinic Based on Treatment and Molecular Factors over a Decade
por: Yang, Jiayu, et al.
Publicado: (2023)

The Occurrence of Richter's Syndrome during Treatment with Obinutuzumab and Chlorambucil
por: Ng, Teng Fong, et al.
Publicado: (2020)

Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia
por: Sharman, Jeff P., et al.
Publicado: (2022)

Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study
por: Fresa, Alberto, et al.
Publicado: (2022)

Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain
por: Casado, Luis Felipe, et al.
Publicado: (2016)

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial
por: Moreno, Carol, et al.
Publicado: (2022)

Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

Frontline Treatment of the Young, Fit Patient with CLL: A Canadian Perspective
por: Costello, Jacqueline, et al.
Publicado: (2021)

A Novel Treatment With Obinutuzumab-Chlorambucil in a Patient With B-Cell Prolymphocytic Leukemia: A Case Report and Review of the Literature
por: Hew, Jason, et al.
Publicado: (2018)

Comparative Efficacy of Ibrutinib Versus Obinutuzumab + Chlorambucil in First-Line Treatment of Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison
por: Van Sanden, Suzy, et al.
Publicado: (2017)

Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study
por: Munir, Talha, et al.
Publicado: (2023)

Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study
por: Visentin, Andrea, et al.
Publicado: (2022)

Experimental Regional Administration (Perfusion and Infusion) of Chlorambucil (p-N, N-Di-(β-Chloroethyl) Aminophenylbutyric Acid)
por: Boyland, E., et al.
Publicado: (1961)

Chlorambucil-Induced Acute Interstitial Pneumonitis
por: Shafqat, Hammad, et al.
Publicado: (2014)

Potent Chlorambucil-Platinum(IV) Prodrugs
por: Aputen, Angelico D., et al.
Publicado: (2022)

Chlorambucil-induced psoriasis: A rare entity
por: Kumar, Sumir, et al.
Publicado: (2020)

Targeting Metabolism and Autophagy in the Context of Haematologic Malignancies
por: Banerji, Versha, et al.
Publicado: (2012)

Chlorambucil and interferon for low grade non-Hodgkin's lymphoma.
por: Rohatiner, A. Z., et al.
Publicado: (1987)

Inhibition of human tumour clonogenicity by chlorambucil and its metabolites.
por: Goodman, G. E., et al.
Publicado: (1982)

Chlorambucil-induced cytomegalovirus infection: a case report
por: López-Lluva, María Thiscal, et al.
Publicado: (2014)

Chlorambucil-monoglutathionyl conjugate is sequestered by human alpha class glutathione S-transferases.
por: Meyer, D. J., et al.
Publicado: (1992)

Disseminated Enteroviral Infection Associated with Obinutuzumab
por: Dendle, Claire, et al.
Publicado: (2015)

Comparison of outcome of patients with CLL who are referred or nonreferred to a specialized CLL clinic: a Canadian population‐based study
por: Beiggi, Sara, et al.
Publicado: (2016)

A Simple in-vitro Test for Assessing the Sensitivity of Lymphocytes to Chlorambucil
por: Lawler, Sylvia D., et al.
Publicado: (1971)

Chlorambucil combination therapy in refractory serpiginous choroiditis: A cure?
por: Maleki, Arash, et al.
Publicado: (2021)

Long-term management of a cat with nasopharyngeal lymphoma by chlorambucil
por: Takahashi, Kaho, et al.
Publicado: (2021)

Chlorambucil-Bearing Hybrid Molecules in the Development of Potential Anticancer Agents
por: Peter, Sijongesonke, et al.
Publicado: (2023)

Chlorambucil plus Rituximab as Front-Line Therapy in Elderly/Unfit Patients Affected by B-Cell Chronic Lymphocytic Leukemia: Results of a Single-Centre Experience
por: Laurenti, Luca, et al.
Publicado: (2013)

Impact of obinutuzumab alone and in combination for follicular lymphoma
por: Sarraf Yazdy, Maryam, et al.
Publicado: (2017)

The clinical development of obinutuzumab for the treatment of follicular lymphoma
por: Ma, Barbara, et al.
Publicado: (2017)

Obinutuzumab is Effective for the Treatment of Refractory Membranous Nephropathy
por: Sethi, Supreet, et al.
Publicado: (2020)

Obinutuzumab Rescue in Rituximab Resistant Mixed Cryoglobulinemia
por: Genest, Dominique S., et al.
Publicado: (2021)

Obinutuzumab: B-cell depletion: case report
Publicado: (2021)

Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region
por: Autore, Francesco, et al.
Publicado: (2020)

The B cell death function of obinutuzumab-HDEL produced in plant (Nicotiana benthamiana L.) is equivalent to obinutuzumab produced in CHO cells
por: Lee, Jin Won, et al.
Publicado: (2018)

P1080: ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY
por: Trotman, Judith, et al.
Publicado: (2023)

Chlorambucil Conjugated Ugi Dendrimers with PAMAM-NH(2) Core and Evaluation of Their Anticancer Activity
por: Seixas, Nalin, et al.
Publicado: (2019)

Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab
por: Freeman, C L, et al.
Publicado: (2016)

The Uptake and Utilization of Chlorambucil by Lymphocytes from Patients with Chronic Lymphocytic Leukaemia
por: Hill, Bridget T., et al.
Publicado: (1972)

Cannot write session to /tmp/vufind_sessions/sess_pstq7f1qd5v6rt4j9lscs72t78